By: Benzinga
UPDATE: Jefferies Initiates Supernus Pharmaceuticals at Buy; Outlook Compelling Ahead of Key Launches
Jefferies initiated coverage on Supernus Pharmaceuticals (NASDAQ: SUPN ) with a Buy rating and a $13.00 price target. Jefferies commented, "With two recently approved epilepsy drugs (each ~$250M peak), pipeline optionality and little binary risk, SUPN offers a compelling risk/reward with only ~$175M EV.Launch expectations have dropped precipitously and although
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here